NEW 6th Edition - 2010

Available for Immediate Download...
Developed and Emerging Markets

                 List Price: $965
     

NEW! pharmahandbook - Volume Licensing Program 

VOI Consulting is pleased to announce volume licensing for our industry standard publication -- pharmahandbook.

(click for details)

pharmahandbook: A Guide to the International Pharmaceutical Industry

NEW 6th Edition - 2010

The prescription drug industry is among the most globalized and the most heavily regulated — in the world. PharmaHandbook™ is an essential resource for anyone required to navigate the complexities of the global pharmaceutical marketplace. Our customers have called PharmaHandbook™ “invaluable”, “extremely useful”, “a wonderful resource” and say they “look forward to receiving it every year.” Details

pharmahandbook™ includes coverage of 37 individual DEVELOPED and EMERGING countries (cumulatively representing more than 99% of worldwide sales), a special section devoted to issues that affect all European Union members and an analysis of the international intellectual property rights system.

( View  Markets)

PharmaHandbook 2010: FAQ

GenericHandbook: A Guide to the Generic Drug Industry

GenericHandbook (provides an in-depth, up-to-date analysis of issues, trends, regulations, markets, companies and products in the U.S. generic drug industry. Topics covered include patent litigation, emerging competition from low-cost providers in China and India, authorized generics, biogenerics, mergers and the impact of a NEW Obama Administration on the Generic Drug Industry. NEW Third Edition Now Shipping!  Details

List Price: $6750

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW! Alzheimer’s Disease: Global Markets, Competitors, Pipelines and Opportunities:

Alzheimer's Disease (AD) is one of the fastest growing areas in pharmaceutical R& D. Worldwide sales are expected to grow by 15% annually between 2006 and 2012 -- approximately three times faster than the industry as a whole. Increasing life-expectancy will result in dramatic growth in the AD patient base along with massive increases in societal costs. A new class of drugs (disease modifiers) will begin to reach the market approximately two to three years from now, changing the dynamics of a category that has long been dominated by a single product.

• Worldwide sales are expected to grow by 15% annually between 2008 and 2012 —more than 3 times faster than the industry as a whole.

• Increasing life expectancy will result in dramatic growth in AD patient base (along with massive increases in societal costs of caring for patients).

• A new category of drugs (disease modifiers) will begin to reach the market in the next few years, changing the dynamics of a category that has long been dominated by a single product.

• Although the need for new therapies is enormous, the road to approval has proven especially difficult for Alzheimer’s drugs.